**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 75596

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Expression of the methylcytosine dioxygenase ten-eleven translocation-2 and connexin 43 in inflammatory bowel disease and colorectal cancer**

El-Harakeh M *et al*. TET-2 and Cx43 in IBD and cancer

Mohammad El-Harakeh, Jessica Saliba, Sharaf Aldeen Kawthar, May Haidar, El Hajjar Layal, Mireille Kallassy Awad, Jana G Hashash, Margret Shirinian, Marwan El-Sabban

**Mohammad El-Harakeh, Sharaf Aldeen Kawthar, May Haidar, El Hajjar Layal, Marwan El-Sabban,** Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut 1107, Lebanon

**Mohammad El-Harakeh, Mireille Kallassy Awad,** UR GPF Laboratory of Biodiversity and Functional Genomics, Faculty of Science, Université Saint-Joseph de Beyrouth, Beirut 1107, Lebanon

**Jessica Saliba,** Department of Biology, Faculty of Sciences, Lebanese University, Beirut 1533, Lebanon

**Jessica Saliba,** Department of Public Health, Faculty of Health Sciences, University of Balamand, Dekwaneh, Sin el Fil 1552, Lebanon

**Jana G Hashash,** Department of Internal Medicine, Division of Gastroenterology and Hepatology, Faculty of Medicine, American University of Beirut, Beirut 1107, Lebanon

**Margret Shirinian,** Department of Experimental Pathology, Immunology and Microbiology, Faculty of Medicine, American University of Beirut, Beirut 1107, Lebanon

**Author contributions:** El-Harakeh M, Saliba J, Haidar M, and Sharaf Aldeen K equally contributed to the study; El-Sabban M conceived and designed the study; Hashash JG, Awad MK, Shirinian M, and El-Sabban M provided the material and resources for the experiments; El-Harakeh M, Haidar M, Sharaf Aldeen K, and El Hajjar L performed the experiments; Saliba J and El-Harakeh M analyzed the data and wrote the manuscript; Shirinian M and Hashash JG critically reviewed the manuscript; Saliba J and El-Sabban M revised the manuscript; All authors read and approved the final version of the manuscript.

**Corresponding author: Marwan El-Sabban, PhD, Professor,** Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Bliss Street, Beirut 1107, Lebanon. me00@aub.edu.lb

**Received:** February 6, 2022

**Revised:** May 6, 2022

**Accepted:** June 13, 2022

**Published online:** October 28, 2022

**Abstract**

BACKGROUND

Inflammatory bowel disease (IBD) constitutes a substantial risk factor for colorectal cancer. Connexin 43 (Cx43) is a protein that forms gap junction (GJ) complexes involved in intercellular communication, and its expression is altered under pathological conditions, such as IBD and cancer. Recent studies have implicated epigenetic processes modulating DNA methylation in the pathogenesis of diverse inflammatory and malignant diseases. The ten-eleven translocation-2 (TET-2) enzyme catalyzes the demethylation, hence, regulating the activity of various cancer-promoting and tumor-suppressor genes.

AIM

To investigate Cx43 and TET-2 expression levels and presence of 5-hydroxymethylcytosine (5-hmC) marks under inflammatory conditions both *in vitro* and *in vivo*.

METHODS

TET-2 expression was evaluated in parental HT-29 cells and in HT-29 cells expressing low or high levels of Cx43, a putative tumor-suppressor gene whose expression varies in IBD and colorectal cancer, and which has been implicated in the inflammatory process and in tumor onset. The dextran sulfate sodium-induced colitis model was reproduced in BALB/c mice to evaluate the expression of TET-2 and Cx43 under inflammatory conditions *in vivo*. In addition, archived colon tissue sections from normal, IBD (ulcerative colitis), and sporadic colon adenocarcinoma patients were obtained and evaluated for the expression of TET-2 and Cx43. Expression levels were reported at the transcriptional level by quantitative real-time polymerase chain reaction, and at the translational level by Western blotting and immunofluorescence.

RESULTS

Under inflammatory conditions, Cx43 and TET-2 expression levels increased compared to non-inflammatory conditions. TET-2 upregulation was more pronounced in Cx43-deficient cells. Moreover, colon tissue sections from normal, ulcerative colitis, and sporadic colon adenocarcinoma patients corroborated that Cx43 expression increased in IBD and decreased in adenocarcinoma, compared to tissues from non-IBD subjects. However, TET-2 expression and 5-hmC mark levels decreased in samples from patients with ulcerative colitis or cancer. Cx43 and TET-2 expression levels were also investigated in an experimental colitis mouse model. Interestingly, mice exposed to carbenoxolone (CBX), a GJ inhibitor, had upregulated TET-2 levels. Collectively, these results show that TET-2 levels and activity increased under inflammatory conditions, in cells downregulating gap junctional protein Cx43, and in colon tissues from mice exposed to CBX.

CONCLUSION

These results suggest that TET-2 expression levels, as well as Cx43 expression levels, are modulated in models of intestinal inflammation. We hypothesize that TET-2 may demethylate genes involved in inflammation and tumorigenesis, such as Cx43, potentially contributing to intestinal inflammation and associated carcinogenesis.

**Key Words:** Demethylation; Inflammation-induced carcinogenesis; Ulcerative colitis; Colorectal cancer; Connexins

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**: El-Harakeh M, Saliba J, Sharaf Aldeen K, Haidar M, El Hajjar L, Awad MK, Hashash JG, Shirinian M, El-Sabban M. Expression of the methylcytosine dioxygenase ten-eleven translocation-2 and connexin 43 in inflammatory bowel disease and colorectal cancer. *World J Gastroenterol* 2022; 28(40): 5845-5864

**URL**: https://www.wjgnet.com/1007-9327/full/v28/i40/5845.htm

**DOI**: https://dx.doi.org/10.3748/wjg.v28.i40.5845

**Core Tip:** Chronic inflammation of the colon is a risk factor for colorectal cancer. Intestinal inflammation has been associated with reduced gap junction-mediated intercellular communication and downregulation connexins [mainly connexin 43 (Cx43)]. The involvement of the demethylating enzyme ten-eleven translocation-2 (TET-2) (methylcytosine dioxygenase) in the inflammatory process has motivated the investigation of Cx43 and TET-2 expression in colitis and colorectal carcinoma. *In vitro* and *in vivo* data report on the upregulation of Cx43 in inflammatory states and a downregulation of TET-2. In human samples of colon adenocarcinoma, both TET-2 and Cx43 were downregulated, potentially implicating them in the malignant transformation of inflamed intestinal tissues.

**INTRODUCTION**

The gastrointestinal tract is constantly exposed to environmental insults that may potentially lead to pathologies. Inflammatory bowel disease (IBD) is a relapsing and remitting inflammatory disorder affecting distinct parts of the gastrointestinal tract. It comprises two primarily encountered disorders: Crohn’s disease and ulcerative colitis, which can be distinguished by their localization in the different parts of the gut and the endoscopic appearance of the inflamed segment[[1-3](#_ENREF_1)]. IBD increases the risk of developing colon adenocarcinoma[[4](#_ENREF_4)], and colitis-associated colon adenocarcinoma remains a fundamental consequence of sustained IBD, possibly because both IBD and colon adenocarcinoma share etiological factors implicated in their development[[5](#_ENREF_5)].

Gap junctions (GJs), components of junctional complexes, have a potential role in regulating epithelial integrity and function. GJs are formed by the docking of two hemichannels (connexin hexamers) contributed from two adjacent cells, allowing the direct exchange of ions and small signaling molecules (< 2 kDa)[[6](#_ENREF_6)]. Connexins play a pivotal role in cellular proliferation, differentiation, and function and are recognized as putative tumor-suppressor genes[[7-9](#_ENREF_7)]. The library of connexin-related diseases has been emerging for many years, and includes various types of syndromes and disorders, such as inflammatory diseases and cancer. Several studies have revealed that the inflammatory response relies in part on connexins and GJ-mediated intercellular communication (GJIC)[[10](#_ENREF_10)]. More specifically, alteration in the expression of connexin 43 (Cx43) in the gastrointestinal tract is associated with IBD, gastrointestinal infections, and impaired motility[[11](#_ENREF_11),[12](#_ENREF_12)]. We have previously shown an alteration of Cx43 expression and localization, as well as a direct heterocellular communication between intestinal epithelial cells (IECs) and macrophages, which may contribute to IBD pathogenesis[[12](#_ENREF_12)].

In complex diseases, such as IBD and colon adenocarcinoma, in addition to the heritable component, environmental and epigenetic (DNA methylation and demethylation, histone marks, higher order chromatin structure, *etc.*) factors are likely to influence onset[[13](#_ENREF_13)]. DNA methylation state is controlled by the interplay between DNA methyltransferases and demethylating enzymes, such as ten-eleven translocation (TET) proteins. Methylation occurs at normally demethylated CpG-rich regions named “CpG islands”, of which 70% overlap with human gene promoters, and results in gene silencing[[14](#_ENREF_14)]. DNA methylation profiles from IBD patients are considerably altered compared to healthy counterparts[[15](#_ENREF_15" \o "Ryan, 2020 #10)]. Moreover, in IBD-associated colon adenocarcinoma, DNA methylation status was distinct from sporadic colon adenocarcinoma, with different gene expression profiles[[16](#_ENREF_16)]. DNA methylation is counteracted by demethylation mechanisms, catalyzed by TET enzymes (TET-1, TET-2, TET-3), thus activating gene transcription[[17](#_ENREF_17)]. Following a series of oxidation reactions by TET enzymes, previously methylated 5-methylcytosine is converted to 5-hydroxymethylcytosine (5-hmC) and further oxidized products that will be recognized and excised by thymine-DNA glycosylase/base enzyme repair pathway to result in an unmethylated cytosine residue[[18](#_ENREF_18)]. TET genes are mutated in a variety of diseases and cancers. In inflammatory diseases, TET-2 is crucial for the repression of the pro-inflammatory cytokine, interleukin (IL)-6[[19](#_ENREF_19)], while in several cancers, TET-2 expression is downregulated[[20](#_ENREF_20)]. In particular, tumors of the digestive tract express different levels of TET enzymes, which are explored as potential factors informing prognosis[[21](#_ENREF_21)]. Downregulation of TET-1, TET-2, and TET-3 have been reported in gastric cancers with concomitant loss of 5-hmC marks[[22](#_ENREF_22)] and in colorectal carcinoma[[23](#_ENREF_23)], with TET-2 transcriptional levels potentially serving as indicators for treatment outcome and disease recurrence[[23](#_ENREF_23)]. In addition, a recent study reported that the human gene coding for TET-2 contains three promoter elements which are differently regulated in different tissues and developmental stages[[24](#_ENREF_24)] and may play a role in cancer development.

While many studies have reported the Cx43 promoter to be hypermethylated during the transition from inflammation to cancer[[25-27](#_ENREF_25)], the expression statuses of Cx43 and TET-2 in IBD and colorectal cancer have not been simultaneously described. This study investigated the effect of inflammation and Cx43 expression levels on the intestinal cell membrane integrity and described TET-2 expression and 5-hmC marks under inflammatory states *in vitro, in vivo*, and in human samples of ulcerative colitis and sporadic colon carcinoma.

**MATERIALS AND METHODS**

***Cell lines and culture conditions***

The HT-29 and Caco-2 cell lines derived from colorectal adenocarcinoma tissues were used as models for human IECs. When grown in monolayer, these cells become more differentiated and IEC-like[[12](#_ENREF_12),28,[29](#_ENREF_29)] and are widely used as a model of intestinal transport and pathology, including inflammation. Human embryonic kidney cells (packaging HEK 293T cells) were used for production of viral supernatant for transduction purposes.

In addition, the human monocytic cell line (THP-1) was used as an *in vitro* model for activated macrophages[[12](#_ENREF_12),30,[31](#_ENREF_31)] for the production of conditioned inflammatory medium. After exposure to phorbol myristate acetate (PMA) and lipopolysaccharide (LPS), THP-1 cells become activated; they adhere to the cell culture vessel and show increased transcriptional levels of connexins, Toll-Like Receptor (TLR)-2, TLR-4, NF-κB p65, COX-2, inflammatory cytokines tumor necrosis factor-α (TNF-α), and IL-1β[[12](#_ENREF_12)]. In this study, suspension THP-1 cells were activated with 50 ng/mL PMA (Sigma-Aldrich, St Louis, MO, United States) for 24 h, followed with 1 μg/mL of LPS (Sigma-Aldrich) for 4 additional hours. When activated THP-1 cells adhered to the cell culture plate, they were washed with PMA- and LPS-free media and left to grow for 72 h. Conditioned media was then collected, filtered, and applied *in vitro* onto colon cell lines to create an inflammatory milieu.

Cells were maintained in complete RPMI-1640 (Sigma-Aldrich) for HT-29 and THP-1 cells or Dulbecco's Modified Eagle's medium (DMEM AQ; Sigma-Aldrich) for HEK 293T cells supplemented with 10% FBS (Sigma-Aldrich), 100 U/mL penicillin G, and 100 μg/mL streptomycin (Sigma-Aldrich). Cells were grown at 37 °C in a humidified incubator with 5% CO2 atmosphere.

***Generation of HT-29 cells upregulating Cx43 gene***

The Cx43-pDendra2N construct (Evrogen, Moscow, Russia) was previously cloned into pCSCW lentiviral vectors[[12](#_ENREF_12)]. The plasmid was then used to transform DH5α competent *Escherichia coli* bacteria, which were then left to proliferate. Plasmid was then isolated and purified using the EndoFree Maxi plasmid purification kit (Qiagen, Hilden, Germany) to be used for transfection along with other plasmids (gag/pol/env) into HEK 293T cells for production of viral supernatant, which carries the Cx43-pDendra2 chimeric proteins. The viral supernatant was used to transduce HT-29 cells. Following the transduction, HT-29 cells were cultured, expanded, and highly positive cells (referred to as HT-29 Cx43D cells thereafter) were sorted using the BD FACSAria™ III sorter (BD Biosciences, Franklin Lakes, NJ, United States). Viral supernatants were obtained from HEK 293T cells and used to transduce HT-29 cells. These cells, named HT-29 Cx43D, were then isolated using a BD Fluorescence-Activated Cell Sorting Aria SORP cell sorter in the single-cell mode. Green fluorescence in HT-29 Cx43D cells attests to the successful upregulation of exogenous Cx43 in these cells.

***Generation of HT-29 cells downregulating Cx43 gene using CRISPR/Cas9 system***

HT-29 cells knocking down Cx43, referred to as HT-29 Cx43- cells, were generated using the CRISPR/Cas9 gene-editing system. After cloning the Cx43 target sequence (20 bp) into the guide RNA scaffold of the pX330-CRISPR plasmid, the bacterial transformation was performed as above and 10-15 colonies were picked to check for the correct insertion of the guide RNA by sequencing. Transfection of HT-29 cells with positive clones was performed, and cells were selected with puromycin (1 μg/mL) until isolated colonies were obtained. Several positive clones were validated for Cx43 knockdown at the RNA and protein levels. One specific clone resulted in more than 90% down-regulation of Cx43 mRNA, generating the experimental HT-29 Cx43- cells. This downregulation was confirmed by western blot and immunofluorescence assays.

***Cell growth assay***

Parental HT-29, HT-29 Cx43D, and HT-29 Cx43- cells were seeded in 24-well plates at a density of 25000 cells/cm2. At 24 h, 48 h, and 72 h, cells were washed with PBS and trypsinized. Viable cells were counted using the trypan blue exclusion dye.

***Evaluation of barrier integrity***

**Trans-epithelial electrical resistance:** This method evaluates barrier integrity of epithelial cells grown in monolayer; by describing the impedance of barrier-forming cell cultures. Briefly, electrodes are placed on both sides of the cellular barrier and an electric current is applied. The resulting current established in the circuit is measured and trans-epithelial electrical resistance (TEER) is calculated. The higher the TEER, the better the membrane integrity[[32](#_ENREF_32" \o "Poenar, 2020 #89)]. In this study, HT-29, HT-29 Cx43D, and HT-29 Cx43- cells were cultured on Transwell® inserts with 0.4 μm-pore size filters (Corning, Corning, NY, United States). TEER was measured on confluent cells in the presence or absence of 2% dextran sulfate sodium (DSS) using an EVOM voltmeter with an ENDOHM-12 (World Precision Instruments, Sarasota, FL, United States). Electrical resistance was expressed as Ω × cm2. DSS was applied onto the cells to reproduce *in vitro* the membrane breach it is known to induce *in vivo* and characterize the loss of membrane integrity. TEER was calculated by subtracting the resistance of blank filters from that of filters covered with a monolayer of parental HT-29, HT-29 Cx43D, or HT-29 Cx43- cells.

***Evans blue assay***

Epithelial cells form tight junctions that prevent paracellular transit. Evans blue is a dye that strongly binds to serum albumin *in vivo* and *in vitro*, becoming a protein tracer[[33](#_ENREF_33)]. When Evans Blue is added on the apical aspect of cells in culture, it is retained in this compartment due to the established epithelial barrier. Any perturbation of barrier integrity will result in seeping of Evans Blue to the basolateral aspect of the cells. HT-29, HT-29 Cx43D, and HT-29 Cx43- cells were grown on transparent PET membrane cell culture inserts with 0.4 μm-pore size (Corning) until confluent (monolayer). Evans Blue solution (Sigma-Aldrich) was prepared in a 1% bovine serum albumin (cell culture grade; GIBCO®, Paisley, Scotland) at a concentration of 170 μg/mL and then filtered through 0.22 μm-filters (Corning®, Wiesbaden, Germany). At confluence, cells were exposed to 2% DSS for 24 h. Cells were then washed twice with PBS and 400 μL of Evans Blue solution were added on top of the cells (seeded in inserts). Plate wells were rinsed and 1 mL of PBS was added into each well. Cells were then incubated at 37 °C. Every 30 min, 200 μL of solution from the well were collected and replaced with fresh 200 μL PBS, for a total of 2 h. The optic density of collected solution was recorded at 630 nm and concentrations of Evans Blue were calculated.

***DSS-induced colitis mouse model***

This study was approved by the Institutional Animal Care and Utilization Committee of the American University of Beirut (IACUCC# 18-03-476). The acute DSS-induced colitis mouse model was performed as previously reported[[34](#_ENREF_34)]. The DSS colitis model in mice is a well-established model for IBD. Using this mouse model, studies have shown disruption of the epithelial barrier function with the infiltration of immune cells, as well as an uncommon production of cytokines[[35](#_ENREF_35),[36](#_ENREF_36)]. In addition, DSS has been previously used *in vitro* to induce a cell membrane breach in a monolayer of colon cells, mimicking the intestinal mucosal barrier. DSS exposure resulted in impairment of protein trafficking and alterations in membrane composition in the intestinal Caco-2 cell line[[37](#_ENREF_37),38], resembling the intestinal mucosa integrity breach that occurs in IBD.

In this study, carbenoxolone (CBX) was used as a non-specific GJ inhibitor, injected intraperitoneally at the dose of 30 mg/kg every other day. Briefly, adult BALB/c male mice were distributed into the following experimental groups, each comprised of five mice; (1) Control group that received normal drinking water with no CBX injections; (2) CBX group that received normal drinking water with CBX injections starting on day 11; (3) DSS group where mice were exposed to 2.5% DSS in their drinking water for 10 d, followed by normal drinking water as of day 11; and (4) DSS + CBX group that received DSS-containing drinking water for 10 d followed by CBX injections. All four groups were given normal drinking water from day 11 to day 21 (end of experimental duration) and body weights were measured daily. All mice were given standard chow *ad libitum* and were housed in a temperature-controlled environment on a 12-h automated light/dark cycle. On day 21, mice were anesthetized with isoflurane and then euthanized by cervical dislocation. Colon lengths were measured using a ruler and colon tissues were collected for histological and molecular examinations to assess tissue integrity and expression of inflammatory markers, Cx43, and TET-2.

***RNA isolation***

**Cells in culture:** Cells were washed with PBS and total RNA was extracted using the RNeasy® Plus mini kit (Qiagen) as *per* manufacturers’ instructions.

**Cryopreserved tissues:** Colon tissues from experimental mice were collected and snap-frozen in liquid nitrogen. RNA was then isolated using TRI reagent (Sigma), as *per* manufacturers’ protocol. Since DSS treatment inhibits mRNA amplification from tissues by quantitative polymerase chain reaction (qPCR) by inhibiting the activities of both polymerase and reverse transcriptase, RNA purification for all samples in all conditions was done by the lithium chloride method according to Viennois *et al*[38].

***qPCR***

One μg of total RNA was reverse-transcribed to cDNA using the iScriptTM cDNA synthesis kit (Bio-Rad, Hercules, CA, United States). qPCR was conducted using a homemade SYBR green mix in a CFX96 system (Bio-Rad). Products were amplified using primers that recognize Cx43, TET-2, IL-1β, TNF-α, and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Table 1). PCR settings were as follows: A pre-cycle at 95 °C for 5 min followed by 40 cycles consisting of 95 °C for 10 s, 52-62 °C for 30 s, and 72 °C for 30 s with a final extra-elongation at 72 °C for 5 min. The fluorescence threshold cycle value (Ct) was obtained for each gene and normalized to the corresponding GAPDH Ct value. All experiments were carried out in technical duplicates and independently performed at least three times.

***Protein extraction and Western blot***

**Cells in culture:** Cells were washed with ice-cold PBS, and scraped on ice in lysis buffer (0.5 M Tris-HCl buffer, pH 6.8; 2% SDS, and 20% glycerol) containing protease and phosphatase inhibitors (Roche, Basel, Switzerland).

**Cryopreserved tissues:** Snap-frozen mouse colon tissues were homogenized on ice in ice-cold RIPA buffer containing 10% of a 0.5 M Tris-HCl buffer, pH 7.5, 3% of 5 M NaCl, 1% NP-40, 10% sodium deoxycholate, and 1% SDS as well as phosphatase and protease inhibitors.

The lysate was then sonicated. Proteins were quantified, loaded onto 10% SDS-polyacrylamide gels, and subjected to electrophoresis. Migrated proteins were transferred to polyvinylidene fluoride membranes (Bio-Rad) and membranes were blocked with 5% fat-free milk in PBS. Membranes were then incubated with either human or mouse primary antibodies for 3 h at room temperature or overnight at 4 °C. Primary antibodies were hybridized with horseradish peroxidase-conjugated secondary antibodies (anti-rabbit: SC-2357 and anti-mouse SC-2005; Santa Cruz Biotechnology, Dallas, TX, United States) and blots were visualized using an enhanced chemiluminescence detection kit. GAPDH (MAB5476; Abnova, Taipei, Taiwan) and β-actin (A2228; Sigma-Aldrich) were used as loading controls. The quantification of bands was performed using the ImageJ software (United States National Institutes of Health, Bethesda, MD, United States). Immunoreactivity of proteins under study was reported as a ratio of protein-of-interest expression to the housekeeping gene used as loading control.

***Specimens from human patients***

Archived formaldehyde-fixed paraffin-embedded (FFPE) colon blocks (ulcerative colitis, sporadic colon adenocarcinoma and normal) were obtained from the American University of Beirut Medical Center. All patients’ identifiers were kept confidential from the study team.

***Histological evaluation***

Sections obtained from animals and human samples were stained with hematoxylin and eosin (H&E) for observation under the light microscope (CX41; Olympus, Tokyo, Japan).

***Immunofluorescence microscopy***

**Cells in culture:** Cells were grown on coverslips and then fixed either with 4% paraformaldehyde and permeabilized with 0.05% Triton X-100 for 20 min for Cx43 probing (SAB4501175; Sigma-Aldrich) or with ice-cold methanol at -20 °C for TET-2 (ab94580; Abcam, Cambridge, United Kingdom) and 5-hmC (ab214728; Abcam) probing before blocking of non-specific binding.

**FFPE tissues:** Human and murine 5-μm-thick tissue sections were immune-stained using antibodies against Cx43, TET-2, 5-hmC, and CD68 (ab201340, Abcam, United States). Briefly, paraffin blocks were sectioned using a microtome and sections were mounted onto glass slides. Specimens were deparaffinized in xylene and rehydrated using a gradient series of alcohol to water. Antigen retrieval was performed by incubating sections in sodium citrate buffer (pH 6.0) in a steamer for 30 min. Sections were allowed to cool, then washed twice with deionized water before blocking of non-specific binding.

Non-specific binding was blocked with 5% normal goat serum (Chemicon, Burlington, MA, United States) in PBS for 1 h in a humidified chamber and incubated with the primary antibody against Cx43, TET-2, and 5-hmC overnight at 4 °C. Cells were then washed and incubated with IgG-conjugated secondary antibody: Either Texas Red (T862; Life Technologies, Carlsbad, CA, United States) or Alexa Fluor 488 (A11070; Life Technologies) at 1 μg/mL for 1 h at room temperature. Nuclei were counterstained with 4′,6-diamidino-2-phenylindole at 1 μg/mL for 10 min. Coverslips were then mounted onto the glass slides using Prolong Anti-fade kit (Life Technologies).

Slides were examined under a fluorescence microscope and images were acquired using a 63×/1.46 Oil Plan-Apochromatic objective (on the laser scanning confocal microscope LSM 710, operated by the Zeiss LSM 710 software; Carl Zeiss, Oberkochen, Germany).

***Statistical analyses***

Numerical values were expressed as mean ± SEM or mean ± SD. The *P* value was determined and considered significant for *P* < 0.05. Differences between experimental groups were assessed using Student *t*-test, one-way analysis of variance (ANOVA) or by two-way ANOVA followed by Tukey's multiple comparisons test.

**RESULTS**

***Characterization of the HT-29 cell model used in this study***

In an attempt to investigate TET-2 modulation in the context of different Cx43 expression levels in HT-29 cells, Cx43 was upregulated (HT-29 Cx43D cells) or downregulated (HT-29 Cx43- cells). Increases and decreases in Cx43 levels were reflected at the translational level: Western blot analysis (Figure 1A) shows upregulation of exogenous Cx43 protein levels in HT-29 Cx43D and loss of endogenous Cx43 protein expression in HT-29 Cx43- cells compared to parental HT-29 cells (*P* < 0.001). Figure 1B also shows increased expression of Cx43 in HT-29 Cx43D cells and their localization at the cell periphery, where they form GJ plaques, and a decrease in Cx43 levels in HT-29 Cx43- cells.

Cells manipulated for *Cx43* gene showed differential proliferation rates 48 h and 72 h post-seeding. As depicted in Figure 1C, Cx43 upregulation (HT-29 Cx43D cells) significantly decreased the number of viable cells compared to parental HT-29 cells (*P* < 0.05 at 48 h and *P* < 0.001 at 72 h). However, cells devoid of Cx43 (HT-29 Cx43- cells) demonstrated a significantly greater proliferation rate compared to parental HT-29 cells at 48 h and 72 h post-seeding (*P* < 0.001). The increased proliferation rate of HT-29 Cx43- cells was also accompanied by increased migratory potential, as suggested by the wound healing and the invasion assays (Supplementary Figure 1). Compared to parental cells, HT-29 Cx43- cells seemed more efficient at closing the artificially created gap (*P* < 0.05).

These observations are in accordance with the tumor suppressor role of Cx43, greatly inhibiting the proliferation of HT-29 cells.

***Modulation of TET expression in HT-29 cellular subsets***

Transcriptional levels of TET-1, TET-2, and TET-3 were evaluated in HT‑29 cells, manipulated for Cx43 expression. TET-2 specifically demonstrated the highest transcriptional levels between all three TET genes (Figure 1D). TET-2 protein expression was verified by immunofluorescence in parental HT-29 cells (Figure 1D). While TET-1 and TET-3 levels were not significantly different in HT-29 cells expressing lower or higher levels of Cx43, TET-2 levels significantly increased in HT-29 Cx43- cells compared to parental HT-29 (*P* < 0.05) and to HT-29 Cx43D (*P* < 0.001) cells.

For the remainder of this study, TET-2 expression levels and 5-hmC mark were evaluated given the greater expression of TET-2 in HT-29 cells and the prevalence of loss-of-function mutations of TET-2 in cancer[[21](#_ENREF_21),[39-41](#_ENREF_39)].

***Inflammation induces increase in Cx43 and TET-2 expression levels in HT-29 cells***

In order to explore a potential pattern of expression for TET-2 and Cx43 in inflammation, parental HT-29, HT-29 Cx43D, and HT-29 Cx43- cells were screened for TET-2 mRNA and protein expressions, as well as 5-hmC marks by immunofluorescence using an antibody against 5-hmC, a product of the reaction catalyzed by TET-2. In Cx43-expressing cells, the addition of inflammatory media (supernatant from activated THP-1 cells) resulted in upregulation of Cx43 (Figure 2A). Similarly, under inflammatory conditions, all three cellular subsets upregulated their TET-2 expression (*P* < 0.05) at the transcriptional and translational levels (Figure 2B). Interestingly, HT-29 cells down-regulating Cx43 showed higher expression of TET-2 compared to parental cells or cells overexpressing Cx43 (Figure 2B). The 5-hmC marks also increased with increased TET-2 levels in HT-29 Cx43- cells. Levels of TET-2 and 5-hmC both increased in cells exposed to inflammation, as shown by quantified immunofluorescence micrographs (Figure 2C). Changes in TET-2 expression were less pronounced in HT-29 Cx43D cells than in HT-29 Cx43- cells. This trend was also evident with the 5-hmC marks (Figure 2C) where increased expression of TET-2 correlated with increased amounts of 5-hmC.

In order to strengthen these findings, experiments were performed on Caco-2 cells. Levels of Cx43 and TET-2 were also upregulated in Caco-2 cells exposed to inflammatory medium (Figure 2D), with a five-fold increase in Cx43 levels (*P* < 0.001) and two-fold increase in TET-2 levels (*P* < 0.01).

***Downregulating Cx43 contributes to the disruption of epithelial membrane integrity***

Parental HT-29, HT-29 Cx43D, and HT-29 Cx43- cells were grown as monolayers and exposed to 2% DSS for 24 h to evaluate if differential Cx43 levels would have any bearing on DSS-induced membrane integrity breach. DSS was previously shown to impair IEC membrane integrity *in vitro*[[42](#_ENREF_42)] and it was used in our study to induce membrane injury similar to that observed upon chronic inflammation. Figure 3A shows that DSS resulted in decreased cell contacts and increased spaces between cells (red arrows), indicating loss of membrane integrity. The TEER assay was performed to assess how Cx43 modulation affects membrane integrity in the presence of DSS. Figure 3B shows that, in the absence of DSS, differentially expressed Cx43 had no major impact on epithelial barrier integrity, with an average TEER of 20 Ω × cm2 in parental and in HT-29 Cx43- cells and 23 Ω × cm2 in HT-29 Cx43D cells. However, the addition of DSS resulted in a significant decrease in TEER values by approximately 37% in parental cells and 50% in HT-29 Cx43- cells (*P* < 0001). Therefore, overexpression of Cx43 in HT-29 Cx43D cells seemed to be protective against DSS-induced loss of membrane integrity (Figure 3B).

The Evans Blue permeability assay was then performed to evaluate the monolayer integrity under DSS exposure and in cells with different Cx43 expression status. The level of cell permeability or “leakage” was correlated to the concentration of Evans Blue measured at the bottom of the well. As shown inFigure 3C, after 60 min of incubation with Evans Blue, the concentration of the dye significantly and rapidly increased in DSS-treated parental HT-29 (*P* < 0.05) and HT-29 Cx43- cells (*P* < 0.0001). However, within the two-hour timeframe, cells overexpressing Cx43 (HT-29 Cx43D cells) had not leaked substantial levels of Evans Blue dye.

DSS was subsequently used to reproduce the murine colitis model to evaluate modulation of Cx43 and TET-2 levels in the inflamed colons of mice.Figure 3D shows that upon exposure of HT-29 cells to DSS *in vitro*, levels of Cx43 and TET-2 vary. Specifically, in Cx43-expressing cells, DSS exposure results in upregulation of Cx43 (*P* < 0.001). Levels of TET-2 also significantly increase in all HT-29 cellular subsets (*P* < 0.01).

In summary, *in vitro* results suggest that inflammation leads to upregulation of Cx43 and of TET-2 in HT-29 cells. TET-2 upregulation was more pronounced in HT-29 cells devoid of Cx43. Moreover, Cx43 knockdown rendered HT-29 cells more sensitive to DSS-induced membrane integrity breach, in favor of a role of Cx43 protein in the maintenance of epithelial barrier integrity. Modulation of Cx43 and TET-2 *in vitro* displayed similar trends whether cells were exposed to conditioned inflammatory media (obtained from activated THP-1 cells) or to DSS (subsequently used in the colitis mouse model).

An established and widely used DSS-induced colitis mouse model was reproduced[[34](#_ENREF_34)] to evaluate Cx43 and TET-2 expression. A subset of mice was also administered CBX, a GJ inhibitor, to examine TET-2 expression modulation in varying functional states of GJs.

***DSS-induced colitis in mice is attenuated by CBX-induced GJ blockade***

The experimental design was as described in Figure 4A, where each group comprised five mice. Body weight was recorded daily, throughout the 21-d experimental duration. Figure 4B reflects weight changes; while mice in the control group (Group 1) consistently gained weight over the 21-d experiment, mice exposed to CBX alone (Group 2) maintained their baseline weight throughout the experiment. On the other hand, DSS-exposed mice lost a moderate amount of weight until day 10, after which they were switched to normal drinking water (Group 3) and their average weight picked up to almost control group levels. Mice in the DSS group who were injected with CBX starting day 11 recovered some of the weight lost until day 10, but did not reach the normal weight recorded in the control group.

At the end of the experimental duration, mice were euthanized and their colons examined and collected for measurement purposes and a biopsy was used for histological and molecular analyses. Histological examination of H&E stained sections of colons showed a disruption of epithelial barrier as well as an increase in infiltrating cells in crypts of colons from DSS-treated mice compared to control. CBX-treated animals seem to have retained (albeit not fully) some normalcy (Figure 4C). DSS-treated mice showed significantly longer colons compared to the control group (*P* < 0.05). CBX significantly reduced the length of DSS-treated colons to approximately normal levels (*P* < 0.05) (Figure 4D).

Levels of inflammatory cytokines, IL-1β and TNF-α, previously shown to be modulated in IBD models[[12](#_ENREF_12),[38](#_ENREF_43),43], were evaluated by qPCR. In accordance with weight changes and colon length indicative of intestinal damage, DSS-treated mice of Group 3 had increased expression of both IL-1β and TNF-α, compared to control Group 1 (*P* < 0.05) (Figure 4E).

These data propose that CBX alleviates DSS-induced inflammation in mice, as demonstrated by normalized colon length and histology, as well as decreased levels of inflammatory mediator transcripts in colon tissues.

***DSS-induced inflammation increases Cx43 and TET-2 expression in vivo***

Colon tissues obtained from mice on day 21 (end of experimental duration) were processed for total RNA and protein extraction. Cx43 expression was significantly higher in tissues from mice exposed to DSS both at the transcriptional (Figure 5A, *P* < 0.0001) and translational levels (Figure 5A, middle and right panels). However, CBX injections restored Cx43 mRNA and protein levels back to control levels. Not only did GJ inhibition attenuate the inflammatory state in the colon, it also led to downregulated Cx43 expression.

Levels of TET-2 were also evaluated in the colon tissues obtained from mice in all four experimental groups. Gene expression analysis pointed to an increase of TET-2 mRNA levels in the CBX-treated group (Group 2, Figure 5B, *P* < 0.001). In the tissues of mice from Group 4 (DSS + CBX), TET-2 levels were similar to those in the DSS group (slightly, but not significantly, higher than control levels). The same pattern was observed at the protein level (Figure 5B, middle and right panels). Changes in TET-2 levels were accompanied by changes in Cx43 levels, which increased in DSS-treated (inflamed) colons and decreased upon addition of CBX (Figure 5C). Inflammation was further underscored by immunostaining using CD68 antibody. As shown in Figure 5D, levels of infiltrated CD68+ cells (macrophages) increased significantly by six-fold in colons of DSS-treated mice as opposed to those of control or CBX-treated mice alone (*P* < 0.0001). In accordance with CBX effects on inflammatory mediators and histological aspects, CBX injections following DSS exposure resulted in a decreased amount of macrophages. Sections from colons of mice in the DSS group also showed considerable levels of TET-2 protein in epithelial cells with neighboring macrophages, both indicative of an active inflammatory process. TET-2 levels increased further in colons of CBX-treated mice. In addition, and consistent with transcriptional and translational data, CBX-treated mice had upregulated TET-2 protein levels in their colons (Figure 5D). Immunofluorescent micrographs reflect TET-2 level increase in mucosal cells, though not to the same extent as qPCR data; due to the contribution of TET-2 mRNA from CD68+ macrophages in the vicinity of IECs.

These data indicate that inhibiting GJs in inflamed tissues mitigates DSS-induced inflammation. In addition, the increase in Cx43 expression upon exposure to DSS is accompanied by an increase in TET-2 protein expression levels, and disabling GJs by CBX is paralleled by a significant increase in TET-2 levels. Data therefore suggest that, under inflammatory conditions (DSS), GJ inhibition by CBX restores Cx43 levels down to control. In accordance with *in vitro* data where HT-29 Cx43- cells had upregulated TET-2 levels, chemical inhibition of Cx43 *in vivo* also was accompanied by increased TET-2 levels.

Collectively, *in vitro* and *in vivo* data indicate that under inflammatory conditions, levels of both TET-2 and Cx43 increase.

***Cx43 levels increase and TET-2 levels decrease in colons of patients with ulcerative colitis***

In an attempt to correlate *in vitro* and *in vivo* findings with clinical data, FFPE colon biopsies from normal non-dysplastic non-inflamed colons (*n* = 7), ulcerative colitis (*n* = 5), and colon adenocarcinoma (*n* = 7) patients were obtained anonymously. Sections were stained with H&E for light microscopy, as well as with antibodies against CD68 (macrophage marker), Cx43, and TET-2 for immunofluorescence analyses.

Histological staining exposed a clearly disorganized intestinal mucosal layer in ulcerative colitis and sporadic colon adenocarcinoma tissues as compared to normal tissues (Figure 6A). The disrupted architecture was due to extensive immune activity in the tissues underlying the mucosa. Figure 6B shows CD68+ macrophages infiltrating tissues from ulcerative colitis patients (*P* < 0.0001), underscoring the inflammatory profile. Tissues obtained from patients with sporadic adenocarcinoma of the colon also displayed macrophage foci, but to a much lesser extent than ulcerative colitis tissues (*P* < 0.001). Although comparable to control in terms of fluorescence intensity, CD68+ cells in the adenocarcinoma specimen were not uniformly distributed in the tissue.

Moreover, Cx43 and TET-2 expression and localization were evaluated by immunofluorescence (Figure 6C and D). Consistent with data obtained *in vitro* (Figures 2 and 3) and *in vivo* (Figure 5), Cx43 protein levels were significantly increased in ulcerative colitis (*i.e.* inflamed) tissues (*P* < 0.005) and sharply decreased in adenocarcinoma. Unlike *in vitro* and *in vivo* data that reflect parallel patterns of Cx43 and TET-2 expression in inflammatory conditions, Cx43 level increase in ulcerative colitis was accompanied by a decrease in TET-2 expression (*P* < 0.001). This observation, however, resembles the *in vitro* scenario illustrated in Figure 2. In fact, while TET-2 expression had increased upon exposure of cells to an inflammatory milieu, Cx43 upregulation in HT-29 Cx43D cells was associated with lower overall TET-2 expression compared to parental cells, and Cx43 knockdown resulted in elevated TET-2 levels.

**DISCUSSION**

In various pathologies, including inflammation and cancer, the alteration of the expression, regulation, and association of junctional complexes with other proteins have been reported. Epigenetic methylation and demethylation processes are also major players in a cell’s malignant transformation. Specifically, GJ-forming Cx43 and demethylating enzyme TET-2 have both been documented to be impaired in inflammation and cancer[[10-12](#_ENREF_10),[19](#_ENREF_19),[20](#_ENREF_20)].

Studies have shown that the inflammatory response relies in part on intercellular communication mediated by channel-forming connexins. The role of GJ-mediated signaling in the initiation of inflammation is mainly through the transfer of ATP between neighboring cells. ATP molecules are then released in the extracellular environment where they act as signaling molecules that activate purinergic receptors, amplifying the inflammatory response[[10](#_ENREF_10)]. Wong *et al*[[11](#_ENREF_11" \o "Wong, 2019 #6)] partly elucidated the role of Cx43 in intestinal epithelial barrier injury. TLR activation in the disrupted intestinal epithelium translates intracellularly into Cx43 transcription, translation, post-translational modification, and assembly into connexons. GJIC regulates intestinal epithelial function during both acute and chronic inflammation[[11](#_ENREF_11" \o "Wong, 2019 #6)]. Furthermore, Al-Ghadban *et al*[[12](#_ENREF_12)] demonstrated a role of GJs in the pathogenesis of IBD by a direct communication between IECs and macrophages enhanced by basement membrane degradation[[12](#_ENREF_12)]. Long-term IBD associates with amplified risk of colon carcinogenesis, and the deregulation of connexin expression is regarded as one of the hallmarks of different cancers. Shilova *et al*[44]reviewed *in vitro* and *in vivo* studies that point at a correlation between the loss of connexin expression and cancer onset. In fact, downregulation of Cx26, Cx32, and Cx43 accompanies the development of human bladder cancer, hepatocarcinoma, and breast cancer, respectively[44]. A recent study on breast cancer proposed that Cx43 upregulation in a triple negative breast cancer cell line led to a reversal of its mesenchymal phenotype *in vitro* and to a decreased metastatic potential *in vivo*[[7](#_ENREF_7)]. While connexin downregulation is observed in many cancers, elevated Cx43 levels have also been associated with increased malignancy. In a hepatocellular carcinoma cell line, Cx43 was shown to enhance malignancy by inhibiting Cx32-mediated GJIC[45], and, in prostate cancer, Cx43 promoted invasion and metastasis[46]. Variability of data on connexin involvement in cancer onset and progression warrants more research to identify the underlying factors that dictate a tumor-suppressing or tumor-enhancing activity of connexins. Epigenetic regulation of various genes could explain the differential expression of tumor-suppressor and tumor-enhancer genes in inflammation and cancer onset and progression.

The role of demethylating enzyme TET-2 in IBD and colorectal adenocarcinoma has not been fully described. In fact, TET proteins have mostly been studied in hematological malignancies. TET-1 was characterized as a partner gene to the *Mixed-Lineage Leukemia* gene in acute myeloid leukemia (AML), and the *TET-2* gene was described in a study on the myelodysplastic syndrome[47]. Recent investigations report that frequent point mutations in the *TET-2* gene can lead to the truncation of the resulting protein and loss of enzymatic activity, reflected by reduced global levels of the 5-hmC marks in AML patients[[41](#_ENREF_41),48]. However, although mutations in the *TET-1* and *TET-3* genes are rare in hematological malignancies compared to *TET-2*, both still exhibit a tumor-suppressor role: TET-1 in B-cell lymphomas[41] and TET-3, together with TET-2, in murine aggressive myeloid cancer[49]. Mutations and reduced expression of TET proteins were also observed in solid tumors, and decreased translational levels of TETs seem like an important hallmark of different cancers, including cancers of the digestive system[50-52].

In addition to carcinogenesis, a study by Zhang *et al*[[19](#_ENREF_19)] shows an anti-inflammatory role for TET-2, which, under inflammatory conditions, repressed IL-6 transcription in dendritic cells and macrophages[[19](#_ENREF_19)]. Moreover, TET-2-deficient bone marrow-derived dendritic cells and macrophages had high transcriptional levels of IL-6 upon LPS challenge. Another study also reported an increase of TET-2 transcriptional levels in colon tissues from patients with IBD[[53](#_ENREF_55)].The present study examined the expression of Cx43 and TET-2 in an *in vitro* model of colon epithelium, where HT-29 cells were used in their parental state or with upregulated or knocked-out Cx43 in the presence or absence of inflammation (induced by DSS or by the addition of an inflammatory medium). A DSS-induced colitis murine model was used to describe how inflammation modulates the expression of Cx43 and TET-2. Data were then compared to Cx43 and TET-2 expression levels in tissues obtained from patients with ulcerative colitis or sporadic colorectal cancer.

Results from this study indicate that knockout of Cx43 in the HT-29 intestinal cell line leads to disruption of membrane integrity exacerbated by the DSS chemical insult. In Cx43-deficient cells and in mice that were subjected to chemical inhibition of GJs by CBX, loss of GJs was paralleled with increased TET-2 expression, further intensified in the presence of inflammation. In fact, inflammation triggered an upregulation of Cx43 and TET-2 expression in all cell subsets, which is in accordance with the literature[[19](#_ENREF_19),[47](#_ENREF_48)]. An exploratory analysis of human colon samples obtained from ulcerative colitis patients revealed an increase in Cx43 and a decrease in TET-2 protein levels accompanied by the disruption of colon architecture. Though these findings are not aligned with the overall trend implicating TET-2 in intestinal inflammatory conditions, little is known about characteristics of patients whose colon biopsies were examined, including potential pharmacological agents that could lead to TET-2 degradation *via* one of the four pathways reviewed by Cong *et al*[[54](#_ENREF_56)] in October 2020: A caspase-dependent pathway, calpain1-promoted degradation of TET-2, proteasome-dependent degradation, and p53-facilitated autophagy of TET-2 proteins[[54](#_ENREF_56)]. Moreover, TET-2 seems to be implicated in both initiation of the inflammatory process by activating innate pro-inflammatory signaling pathways and its resolution by inducing the repression of pro-inflammatory mediators[[55](#_ENREF_56)]. Therefore, the exact status of TET-2 in the colon of IBD patients remains to be elucidated, in light of multiple factors governing post-transcriptional and post-translational TET-2 regulation. In specimens from sporadic colon adenocarcinoma, both TET-2 and Cx43 proteins were considerably downregulated, underscoring the tumor-suppressor role of Cx43.

In the context of IBD (specifically ulcerative colitis) and colon cancer, we propose that Cx43 upregulation in inflamed colons could attenuate or slow down the onset of malignancy. Therefore, loss of Cx43 in tissues from colon cancer could be attributed to a malignant switch, turning off tumor-suppressor genes and activating tumor-promoting genes. The presence of CD68+ cells (macrophages) was concomitant with loss of TET-2 expression in the colon adenocarcinoma samples. This could be explained by an immune-active phenotype in tumors, with tumor-associated macrophages having little to no TET-2 expression[[55](#_ENREF_57)]. A 2018 study reported increased levels of TET-2 in T lymphocytes from colorectal tumor tissues, leading to demethylation and activation of FOXP3 and regulation of regulatory T cell (Treg) function[[56](#_ENREF_58)], further implicating TET-2 in immune-related processes. In particular, TET-2 has been reported to regulate the innate immune response[[57](#_ENREF_59),[58](#_ENREF_60)]. While it serves to activate the inflammatory response, TET-2 has also been implicated in inflammation resolution, where in response to IL-1/RMyD88 signaling, TET-2 downregulates the expression of inflammatory cytokines, such as IL-6 in innate myeloid cells and IL-1β in macrophages by recruiting HDACs for histone deacetylation[[19](#_ENREF_19),[57](#_ENREF_59)]. This property might explain low levels of TET-2 in human ulcerative colitis samples where unresolved inflammation can be attributed to persistent inflammatory cytokines.

TET-2 status and role in digestive cancers remain unclear and variable, depending on the cancer site and grade, but also on possible mutations that could lead to cancer progression and resistance to chemotherapy, as recently reviewed[[21](#_ENREF_21)].

**CONCLUSION**

Data presented in this manuscript show that exposure of intestinal cells to inflammation is associated with Cx43 and TET-2 upregulation *in* *vitro* and *in vivo.* We propose that, as part of its potential anti-inflammatory role and through its demethylating activity, TET-2 might be responsible for promoting the expression of anti-inflammatory genes and for indirectly repressing the expression of pro-inflammatory genes under inflammatory conditions. Similarly, we hypothesize that the demethylating TET-2 enzyme might promote the expression of tumor-suppressor genes (among others, Cx43) in the inflamed colon. Extrapolating from observations made on human colon samples, a malignant switch could happen in chronically inflamed colons. This malignant switch could be associated with downregulation of TET-2 (and potentially other TET enzymes[[20](#_ENREF_20),[23](#_ENREF_23)]) in ulcerative colitis, possibly resulting in the hypermethylation of genes that are relevant in the context of carcinogenesis, such as Cx43. Although we present evidence on the modulation of TET-2 expression and we reiterate the role of Cx43 in intestinal inflammation, further investigation is under way to more solidly explore the mechanism of action behind a potential interplay between Cx43 and TET-2 that might, at least partly and indirectly, bridge chronic inflammation (such as in IBD) and IBD-induced carcinogenesis in the colon.

**ARTICLE HIGHLIGHTS**

***Research background***

Patients with inflammatory bowel disease (IBD) have a higher propensity to acquire colorectal cancer. The link between inflammation and cancer has long been established; however, the molecular players in the switch to cancer are still poorly defined.

***Research motivation***

In previous work, we have demonstrated a potential role for connexin 43 (Cx43) in inflamed intestinal cells. Recognizing the tumor-suppressor role of Cx43 in several cancers, we set out to explore whether the loss of Cx43 is associated with the switch to carcinogenesis. One potential mechanism for downregulating Cx43 expression is through methylation. We hypothesized that ten-eleven translocation-2 (TET-2), a demethylating enzyme, previously described to have a role in inflammation, may be involved in this process.

***Research objectives***

Using cell culture, a colitis animal model, and archived human tissues, we assessed the expression of both Cx43 and TET-2 in intestinal inflammation. Specific objectives include: (1) Assessment of the expression levels of Cx43 and TET-2 under inflammatory conditions; (2) Assessment of the expression and activity of TET-2 in HT-29 cell lines with up- or down-regulated for Cx43 expression; (3) Reproduction of a colitis mouse model and assessment of Cx43 and TET-2 levels in colons of mice; and (4) Explore Cx43 and TET-2 expression levels in archived biopsies obtained from patients with ulcerative colitis and colon adenocarcinoma.

***Research methods***

This study employed several modalities to verify the hypothesis, which include intestinal epithelial cell (IEC) line modified for Cx43 expression grown under inflammatory conditions. A dextran sulfate sodium-induced colitis mouse model was reproduced and tissues from different experimental conditions were analyzed. Gene expression profile, protein expression levels, morphology and cellular localization were described. In addition, archived formalin-fixed paraffin-embedded tissues were sectioned and evaluated for Cx43 and TET-2 expression.

***Research results***

In vitro, TET-2 expression was elevated under inflammatory conditions and even more so in HT-29 cells devoid of Cx43. The barrier function of IECs was breached when Cx43 levels were down-regulated. These results were corroborated in the murine colitis model. In archived biopsies from ulcerative colitis patients, Cx43 expression was upregulated compared to non-inflamed counterparts. In sporadic colon adenocarcinoma sections, both TET-2 and Cx43 expression levels were decreased.

***Research conclusions***

Under inflammatory conditions, levels of Cx43 and of the demethylating enzyme TET-2 are upregulated. Through demethylation, TET-2 would turn on the expression of several factors involved in inflammation (presumably Cx43 included). When TET-2 levels were diminished in sporadic colon adenocarcinoma, we also observed that Cx43 was downregulated, which may indicate a role of TET-2 in shutting down Cx43 and its tumor-suppressing potential.

***Research perspectives***

*In vitro*, manipulation of TET-2 levels in intestinal cells may yield further insight into the mechanism of action. Methylation studies will also be undertaken. The animal model will be expanded to allow for the development of colon carcinoma, and timed evaluation of molecular players will be performed. More stringent criteria will be implemented for prospective tissue collection from non-inflamed subjects, patients with IBD, and with IBD-associated colorectal cancer.

**REFERENCES**

1 **Khor B**, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. *Nature* 2011; **474**: 307-317 [PMID: 21677747 DOI: 10.1038/nature10209]

2 **Gajendran M**, Loganathan P, Catinella AP, Hashash JG. A comprehensive review and update on Crohn**'**s disease. *Dis Mon* 2018; **64**: 20-57 [PMID: 28826742 DOI: 10.1016/j.disamonth.2017.07.001]

3 **Gajendran M**, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. *Dis Mon* 2019; **65**: 100851 [PMID: 30837080 DOI: 10.1016/j.disamonth.2019.02.004]

4 **Fleming M**, Ravula S, Tatishchev SF, Wang HL. Colorectal carcinoma: Pathologic aspects. *J Gastrointest Oncol* 2012; **3**: 153-173 [PMID: 22943008 DOI: 10.3978/j.issn.2078-6891.2012.030]

5 **Du L**, Kim JJ, Shen J, Chen B, Dai N. KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis. *Oncotarget* 2017; **8**: 22175-22186 [PMID: 28077799 DOI: 10.18632/oncotarget.14549]

6 **Beyer EC**, Berthoud VM. Gap junction gene and protein families: Connexins, innexins, and pannexins. *Biochim Biophys Acta Biomembr* 2018; **1860**: 5-8 [PMID: 28559187 DOI: 10.1016/j.bbamem.2017.05.016]

7 **Kazan JM**, El-Saghir J, Saliba J, Shaito A, Jalaleddine N, El-Hajjar L, Al-Ghadban S, Yehia L, Zibara K, El-Sabban M. Cx43 Expression Correlates with Breast Cancer Metastasis in MDA-MB-231 Cells In Vitro, In a Mouse Xenograft Model and in Human Breast Cancer Tissues. *Cancers (Basel)* 2019; **11** [PMID: 30939738 DOI: 10.3390/cancers11040460]

8 **Kou Y**, Ji L, Wang H, Wang W, Zheng H, Zou J, Liu L, Qi X, Liu Z, Du B, Lu L. Connexin 43 upregulation by dioscin inhibits melanoma progression *via* suppressing malignancy and inducing M1 polarization. *Int J Cancer* 2017; **141**: 1690-1703 [PMID: 28677156 DOI: 10.1002/ijc.30872]

9 **Zhou JZ**, Riquelme MA, Gu S, Kar R, Gao X, Sun L, Jiang JX. Osteocytic connexin hemichannels suppress breast cancer growth and bone metastasis. *Oncogene* 2016; **35**: 5597-5607 [PMID: 27041582 DOI: 10.1038/onc.2016.101]

10 **Willebrords J**, Crespo Yanguas S, Maes M, Decrock E, Wang N, Leybaert L, Kwak BR, Green CR, Cogliati B, Vinken M. Connexins and their channels in inflammation. *Crit Rev Biochem Mol Biol* 2016; **51**: 413-439 [PMID: 27387655 DOI: 10.1080/10409238.2016.1204980]

11 **Wong J**, Chopra J, Chiang LLW, Liu T, Ho J, Wu WKK, Tse G, Wong SH. The Role of Connexins in Gastrointestinal Diseases. *J Mol Biol* 2019; **431**: 643-652 [PMID: 30639409 DOI: 10.1016/j.jmb.2019.01.007]

12 **Al-Ghadban S**, Kaissi S, Homaidan FR, Naim HY, El-Sabban ME. Cross-talk between intestinal epithelial cells and immune cells in inflammatory bowel disease. *Sci Rep* 2016; **6**: 29783 [PMID: 27417573 DOI: 10.1038/srep29783]

13 **Amatullah H**, Jeffrey KL. Epigenome-metabolome-microbiome axis in health and IBD. *Curr Opin Microbiol* 2020; **56**: 97-108 [PMID: 32920333 DOI: 10.1016/j.mib.2020.08.005]

14 **Grosser C**, Wagner N, Grothaus K, Horsthemke B. Altering TET dioxygenase levels within physiological range affects DNA methylation dynamics of HEK293 cells. *Epigenetics* 2015; **10**: 819-833 [PMID: 26186463 DOI: 10.1080/15592294.2015.1073879]

15 **Ryan FJ**, Ahern AM, Fitzgerald RS, Laserna-Mendieta EJ, Power EM, Clooney AG, O'Donoghue KW, McMurdie PJ, Iwai S, Crits-Christoph A, Sheehan D, Moran C, Flemer B, Zomer AL, Fanning A, O'Callaghan J, Walton J, Temko A, Stack W, Jackson L, Joyce SA, Melgar S, DeSantis TZ, Bell JT, Shanahan F, Claesson MJ. Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease. *Nat Commun* 2020; **11**: 1512 [PMID: 32251296 DOI: 10.1038/s41467-020-15342-5]

16 **Pekow J**, Hernandez K, Meckel K, Deng Z, Haider HI, Khalil A, Zhang C, Talisila N, Siva S, Jasmine F, Li YC, Rubin DT, Hyman N, Bissonnette M, Weber C, Kibriya MG. IBD-associated Colon Cancers Differ in DNA Methylation and Gene Expression Profiles Compared With Sporadic Colon Cancers. *J Crohns Colitis* 2019; **13**: 884-893 [PMID: 30753380 DOI: 10.1093/ecco-jcc/jjz014]

17 **Liu XS**, Wu H, Ji X, Stelzer Y, Wu X, Czauderna S, Shu J, Dadon D, Young RA, Jaenisch R. Editing DNA Methylation in the Mammalian Genome. *Cell* 2016; **167**: 233-247.e17 [PMID: 27662091 DOI: 10.1016/j.cell.2016.08.056]

18 **Wawrzyniak M**, Scharl M. Genetics and epigenetics of inflammatory bowel disease. *Swiss Med Wkly* 2018; **148**: w14671 [PMID: 30378641 DOI: 10.4414/smw.2018.14671]

19 **Zhang Q**, Zhao K, Shen Q, Han Y, Gu Y, Li X, Zhao D, Liu Y, Wang C, Zhang X, Su X, Liu J, Ge W, Levine RL, Li N, Cao X. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. *Nature* 2015; **525**: 389-393 [PMID: 26287468 DOI: 10.1038/nature15252]

20 **Rasmussen KD**, Helin K. Role of TET enzymes in DNA methylation, development, and cancer. *Genes Dev* 2016; **30**: 733-750 [PMID: 27036965 DOI: 10.1101/gad.276568.115]

21 **Wang F**, Zhang J, Qi J. Ten-eleven translocation-2 affects the fate of cells and has therapeutic potential in digestive tumors. *Chronic Dis Transl Med* 2019; **5**: 267-272 [PMID: 32055786 DOI: 10.1016/j.cdtm.2019.12.001]

22 **Du C**, Kurabe N, Matsushima Y, Suzuki M, Kahyo T, Ohnishi I, Tanioka F, Tajima S, Goto M, Yamada H, Tao H, Shinmura K, Konno H, Sugimura H. Robust quantitative assessments of cytosine modifications and changes in the expressions of related enzymes in gastric cancer. *Gastric Cancer* 2015; **18**: 516-525 [PMID: 25098926 DOI: 10.1007/s10120-014-0409-4]

23 **Rawłuszko-Wieczorek AA**, Siera A, Horbacka K, Horst N, Krokowicz P, Jagodziński PP. Clinical significance of DNA methylation mRNA levels of TET family members in colorectal cancer. *J Cancer Res Clin Oncol* 2015; **141**: 1379-1392 [PMID: 25557833 DOI: 10.1007/s00432-014-1901-2]

24 **Lou H**, Li H, Ho KJ, Cai LL, Huang AS, Shank TR, Verneris MR, Nickerson ML, Dean M, Anderson SK. The Human *TET2* Gene Contains Three Distinct Promoter Regions With Differing Tissue and Developmental Specificities. *Front Cell Dev Biol* 2019; **7**: 99 [PMID: 31231651 DOI: 10.3389/fcell.2019.00099]

25 **Aasen T**, Leithe E, Graham SV, Kameritsch P, Mayán MD, Mesnil M, Pogoda K, Tabernero A. Connexins in cancer: bridging the gap to the clinic. *Oncogene* 2019; **38**: 4429-4451 [PMID: 30814684 DOI: 10.1038/s41388-019-0741-6]

26 **Wang Y**, Huang LH, Xu CX, Xiao J, Zhou L, Cao D, Liu XM, Qi Y. Connexin 32 and 43 promoter methylation in Helicobacter pylori-associated gastric tumorigenesis. *World J Gastroenterol* 2014; **20**: 11770-11779 [PMID: 25206281 DOI: 10.3748/wjg.v20.i33.11770]

27 **Yi ZC**, Wang H, Zhang GY, Xia B. Downregulation of connexin 43 in nasopharyngeal carcinoma cells is related to promoter methylation. *Oral Oncol* 2007; **43**: 898-904 [PMID: 17306607 DOI: 10.1016/j.oraloncology.2006.11.004]

28 **Ferraretto A**, Bottani M, De Luca P, Cornaghi L, Arnaboldi F, Maggioni M, Fiorilli A, Donetti E. Morphofunctional properties of a differentiated Caco2/HT-29 co-culture as an *in vitro* model of human intestinal epithelium. *Biosci Rep* 2018; **38** [PMID: 29540534 DOI: 10.1042/BSR20171497]

29 **Lea T**, Verhoeckx K, Cotter P, López-Expósito I, Kleiveland C, Lea T, Mackie A, Requena T, Swiatecka D, Wichers H. Caco-2 Cell Line. In: The Impact of Food Bioactives on Health: in vitro and ex vivo models [Internet]. Cham (CH): Springer; 2015. Chapter 10 [PMID: 29787057]

30 **Hyun J**, Romero L, Riveron R, Flores C, Kanagavelu S, Chung KD, Alonso A, Sotolongo J, Ruiz J, Manukyan A, Chun S, Singh G, Salas P, Targan SR, Fukata M. Human intestinal epithelial cells express interleukin-10 through Toll-like receptor 4-mediated epithelial-macrophage crosstalk. *J Innate Immun* 2015; **7**: 87-101 [PMID: 25171731 DOI: 10.1159/000365417]

31 **Sáez PJ**, Shoji KF, Aguirre A, Sáez JC. Regulation of hemichannels and gap junction channels by cytokines in antigen-presenting cells. *Mediators Inflamm* 2014; **2014**: 742734 [PMID: 25301274 DOI: 10.1155/2014/742734]

32 **Poenar DP**, Yang G, Wan WK, Feng S. Low-Cost Method and Biochip for Measuring the Trans-Epithelial Electrical Resistance (TEER) of Esophageal Epithelium. *Materials (Basel)* 2020; **13** [PMID: 32443854 DOI: 10.3390/ma13102354]

33 **Yao L**, Xue X, Yu P, Ni Y, Chen F. Evans Blue Dye: A Revisit of Its Applications in Biomedicine. *Contrast Media Mol Imaging* 2018; **2018**: 7628037 [PMID: 29849513 DOI: 10.1155/2018/7628037]

34 **Mizoguchi A**. Animal models of inflammatory bowel disease. *Prog Mol Biol Transl Sci* 2012; **105**: 263-320 [PMID: 22137435 DOI: 10.1016/B978-0-12-394596-9.00009-3]

35 **Dieleman LA**, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. *Gastroenterology* 1994; **107**: 1643-1652 [PMID: 7958674 DOI: 10.1016/0016-5085(94)90803-6]

36 **Kitajima S**, Takuma S, Morimoto M. Tissue distribution of dextran sulfate sodium (DSS) in the acute phase of murine DSS-induced colitis. *J Vet Med Sci* 1999; **61**: 67-70 [PMID: 10027168 DOI: 10.1292/jvms.61.67]

37 **Toutounji M**, Wanes D, El-Harakeh M, El-Sabban M, Rizk S, Naim HY. Dextran Sodium Sulfate-Induced Impairment of Protein Trafficking and Alterations in Membrane Composition in Intestinal Caco-2 Cell Line. *Int J Mol Sci* 2020; **21** [PMID: 32326391 DOI: 10.3390/ijms21082726]

38 **Viennois E**, Chen F, Laroui H, Baker MT, Merlin D. Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: lithium chloride purification, a rapid and efficient technique to purify RNA. *BMC Res Notes* 2013; **6**: 360 [PMID: 24010775 DOI: 10.1186/1756-0500-6-360]

39 **Feng Y**, Li X, Cassady K, Zou Z, Zhang X. TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair. *Front Oncol* 2019; **9**: 210 [PMID: 31001476 DOI: 10.3389/fonc.2019.00210]

40 **Ko M**, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. *Nature* 2010; **468**: 839-843 [PMID: 21057493 DOI: 10.1038/nature09586]

41 **Weissmann S**, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A. Landscape of TET2 mutations in acute myeloid leukemia. *Leukemia* 2012; **26**: 934-942 [PMID: 22116554 DOI: 10.1038/leu.2011.326]

42 **Homaidan FR**, Chakroun, Dbaibo GS, El-Assaad W, El-Sabban ME. IL-1 activates two phospholipid signaling pathways in intestinal epithelial cells. *Inflamm Res* 2001; **50**: 375-381 [PMID: 11506393 DOI: 10.1007/PL00000259]

43 **Homaidan FR**, El-Sabban ME, Chakroun I, El-Sibai M, Dbaibo GS. IL-1 stimulates ceramide accumulation without inducing apoptosis in intestinal epithelial cells. *Mediators Inflamm* 2002; **11**: 39-45 [PMID: 11926594 DOI: 10.1080/09629350210313]

44 **Shilova ON**, Shilov ES, Lieber A, Deyev SM. Disassembling a cancer puzzle: Cell junctions and plasma membrane as targets for anticancer therapy. *J Control Release* 2018; **286**: 125-136 [PMID: 30030181 DOI: 10.1016/j.jconrel.2018.07.030]

45 **Zhang D**, Kaneda M, Nakahama K, Arii S, Morita I. Connexin 43 expression promotes malignancy of HuH7 hepatocellular carcinoma cells *via* the inhibition of cell-cell communication. *Cancer Lett* 2007; **252**: 208-215 [PMID: 17275998 DOI: 10.1016/j.canlet.2006.12.024]

46 **Zhang A**, Hitomi M, Bar-Shain N, Dalimov Z, Ellis L, Velpula KK, Fraizer GC, Gourdie RG, Lathia JD. Connexin 43 expression is associated with increased malignancy in prostate cancer cell lines and functions to promote migration. *Oncotarget* 2015; **6**: 11640-11651 [PMID: 25960544 DOI: 10.18632/oncotarget.3449]

47 **Langemeijer SM**, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens-Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH. Acquired mutations in TET2 are common in myelodysplastic syndromes. *Nat Genet* 2009; **41**: 838-842 [PMID: 19483684 DOI: 10.1038/ng.391]

48 **Zhao Z**, Chen L, Dawlaty MM, Pan F, Weeks O, Zhou Y, Cao Z, Shi H, Wang J, Lin L, Chen S, Yuan W, Qin Z, Ni H, Nimer SD, Yang FC, Jaenisch R, Jin P, Xu M. Combined Loss of Tet1 and Tet2 Promotes B Cell, but Not Myeloid Malignancies, in Mice. *Cell Rep* 2015; **13**: 1692-1704 [PMID: 26586431 DOI: 10.1016/j.celrep.2015.10.037]

49 **Zibara K**, Awada Z, Dib L, El-Saghir J, Al-Ghadban S, Ibrik A, El-Zein N, El-Sabban M. Anti-angiogenesis therapy and gap junction inhibition reduce MDA-MB-231 breast cancer cell invasion and metastasis *in vitro* and in vivo. *Sci Rep* 2015; **5**: 12598 [PMID: 26218768 DOI: 10.1038/srep12598]

50 **Yang H**, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, Xu ZD, Zhu HG, Ling ZQ, Ye D, Guan KL, Xiong Y. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. *Oncogene* 2013; **32**: 663-669 [PMID: 22391558 DOI: 10.1038/onc.2012.67]

51 **Lian CG**, Xu Y, Ceol C, Wu F, Larson A, Dresser K, Xu W, Tan L, Hu Y, Zhan Q, Lee CW, Hu D, Lian BQ, Kleffel S, Yang Y, Neiswender J, Khorasani AJ, Fang R, Lezcano C, Duncan LM, Scolyer RA, Thompson JF, Kakavand H, Houvras Y, Zon LI, Mihm MC Jr, Kaiser UB, Schatton T, Woda BA, Murphy GF, Shi YG. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. *Cell* 2012; **150**: 1135-1146 [PMID: 22980977 DOI: 10.1016/j.cell.2012.07.033]

52 **Liu C**, Liu L, Chen X, Shen J, Shan J, Xu Y, Yang Z, Wu L, Xia F, Bie P, Cui Y, Bian XW, Qian C. Decrease of 5-hydroxymethylcytosine is associated with progression of hepatocellular carcinoma through downregulation of TET1. *PLoS One* 2013; **8**: e62828 [PMID: 23671639 DOI: 10.1371/journal.pone.0062828]

53 **Cong B**, Zhang Q, Cao X. The function and regulation of TET2 in innate immunity and inflammation. *Protein Cell* 2021; **12**: 165-173 [PMID: 33085059 DOI: 10.1007/s13238-020-00796-6]

54 **Dziaman T**, Gackowski D, Guz J, Linowiecka K, Bodnar M, Starczak M, Zarakowska E, Modrzejewska M, Szpila A, Szpotan J, Gawronski M, Labejszo A, Liebert A, Banaszkiewicz Z, Klopocka M, Foksinski M, Marszalek A, Olinski R. Characteristic profiles of DNA epigenetic modifications in colon cancer and its predisposing conditions-benign adenomas and inflammatory bowel disease. *Clin Epigenetics* 2018; **10**: 72 [PMID: 29875879 DOI: 10.1186/s13148-018-0505-0]

55 **Pan W**, Zhu S, Qu K, Meeth K, Cheng J, He K, Ma H, Liao Y, Wen X, Roden C, Tobiasova Z, Wei Z, Zhao J, Liu J, Zheng J, Guo B, Khan SA, Bosenberg M, Flavell RA, Lu J. The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression. *Immunity* 2017; **47**: 284-297.e5 [PMID: 28813659 DOI: 10.1016/j.immuni.2017.07.020]

56 **Ma H**, Gao W, Sun X, Wang W. STAT5 and TET2 Cooperate to Regulate FOXP3-TSDR Demethylation in CD4+ T Cells of Patients with Colorectal Cancer. *J Immunol Res* 2018; **2018**: 6985031 [PMID: 30013992 DOI: 10.1155/2018/6985031]

57 **Cull AH**, Snetsinger B, Buckstein R, Wells RA, Rauh MJ. Tet2 restrains inflammatory gene expression in macrophages. *Exp Hematol* 2017; **55**: 56-70.e13 [PMID: 28826859 DOI: 10.1016/j.exphem.2017.08.001]

58 **Montagner S**, Leoni C, Emming S, Della Chiara G, Balestrieri C, Barozzi I, Piccolo V, Togher S, Ko M, Rao A, Natoli G, Monticelli S. TET2 Regulates Mast Cell Differentiation and Proliferation through Catalytic and Non-catalytic Activities. *Cell Rep* 2016; **15**: 1566-1579 [PMID: 27160912 DOI: 10.1016/j.celrep.2016.04.044]

**Footnotes**

**Institutional review board statement:** Archived formaldehyde-fixed paraffin-embedded (FFPE) colon blocks (ulcerative colitis, sporadic colon adenocarcinoma and normal) were obtained from the American University of Beirut Medical Center (AUBMC). All patients’ identifiers were kept confidential and all samples were anonymous, hence exempted from ethics committee approval.

**Institutional animal care and use committee statement:** All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of the American University of Beirut, No. 18-03-476.

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Data sharing statement:** Raw data are available upon reasonable request.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** February 6, 2022

**First decision:** April 10, 2022

**Article in press:** June 13, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Lebanon

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): E

**P-Reviewer:** Feng Y, China; Ruan X, China; Wan XH, China **A-Editor:** Nakaji K, Japan **S-Editor:** Fan JR **L-Editor:** Filipodia **P-Editor:** Cai YX

**Figure Legends**

图形用户界面

中度可信度描述已自动生成

**Figure 1 Characterization of the *in vitro* HT-29 cell model.** A: Western blot of connexin 43 (Cx43) protein expression in parental HT-29, HT-29 Cx43-Dendra (Cx43D), and in HT-29 Cx43- cells. Bar graphs display mean densitometric analysis (of three independent experiments) after normalizing protein expression to glyceraldehyde 3-phosphate dehydrogenase (GAPDH); B: Immunofluorescence micrographs of parental HT-29 and HT-29 Cx43- cells, as well as a fluorescent micrograph of HT-29 cells transduced with the GFP-Cx43 construct. Highly GFP positive cells were sorted using BD-Fluorescence-Activated Cell Sorting cell sorter, generating the HT-29 Cx43D. Scale bar 10 μm; C: Cells were counted at three different time points (24, 48 and 72 h), using the trypan blue dye exclusion assay. Compared to parental HT-29 cells, HT-29 Cx43D cells had a slower proliferation rate and HT-29 Cx43- cells a faster proliferation rate at 48 and 72 h; D: Histograms show normalized gene expression of ten-eleven translocation (TETs) in parental HT-29, HT-29 Cx43D and HT-29 Cx43- cells, as detected by quantitative polymerase chain reaction (qPCR). TET-2 was the highest expressed TET in HT-29 cells, and cells with differential Cx43 expression also had significantly different TET-2 expression levels. The inset is an immunomicrograph of TET-2 in HT-29 C43D cells. Scale bar 5 μm. Results are presented as means ± SEM of three independent qPCR runs in duplicates. One-way ANOVA, a*P* < 0.05; b*P* < 0.001; c*P* < 0.0005. Cx43: Connexin 43; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase.

图示, 工程绘图

描述已自动生成

**Figure 2 Connexin 43 and ten-eleven translocation-2 expression increases in cells exposed to inflammation.** Parental HT-29, HT-29 connexin 43-Dendra (Cx43D), and HT-29 Cx43- cells were exposed to inflammatory conditioned media (CM) obtained from activated THP-1 cells for 24 h. A: Histograms show the normalized gene expression of Cx43, as detected by quantitative polymerase chain reaction. Cx43 mRNA levels increase in parental HT-29 and HT-29 Cx43D, in the presence of inflammatory media. Western blot of endogenous Cx43 and exogenous Cx43D protein expression in parental HT-29, HT-29 Cx43D, and in HT-29 Cx43- cells. Densitometric analysis (ratio of protein-of-interest to loading control band intensity) shows a slight increase in Cx43 levels upon exposure to inflammation; B: Bar graphs show ten-eleven translocation-2 (TET-2) transcriptional levels increase in all three HT-29 cellular subsets when exposed to CM. Western blots of TET-2 and densitometric analysis shows increased protein levels of TET-2 in CM-treated cells; C: Immunofluorescence images showing TET-2 expression and 5-hmC marks in parental HT-29, HT-29 Cx43D, and HT-29 Cx43- cells. Bar graphs in the right panel reflect mean fluorescence intensity of at least five different fields acquired from three different experiments. Levels and activity of TET-2 increase in all CM-exposed cells. Scale bar 5 μm; D: Bar graphs display levels of Cx43 and TET-2 in Caco-2 cells exposed to CM. Fluorescent micrographs show increased levels of TET-2 in the nucleus upon exposure to CM. Scale bar 5 μm. Experiments were repeated at least three different times. One-way ANOVA, a*P* < 0.05; b*P* < 0.001; c*P* < 0.0005. TET-2: Translocation-2; Cx43: Connexin 43; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; MFI: Mean fluorescence intensity.

图示

描述已自动生成

**Figure 3 Dextran sulfate sodium treatment disrupts the integrity and permeability of intestinal epithelial barrier, notably in HT-29 connexin 43- cells.** A: Light microscopy images of HT-29 cells in the presence or absence of 2% dextran sulfate sodium (DSS). Scale bar 50 μm; B: The membrane integrity of parental HT-29, HT-29 connexin 43-Dendra (Cx43D), and HT-29 Cx43- cells in the presence or absence of 2% DSS was measured by trans-epithelial electrical resistance (TEER). Bar graphs indicate average TEER measurements; C: Membrane permeability was evaluated by Evans Blue permeability assay in all three cell subsets. Levels of Evans Blue that crossed are measured by spectrophotometry and are plotted as means over time; D: Quantitative polymerase chain reaction data show that transcriptional levels of Cx43 and ten-eleven translocation-2 (TET-2) significantly increase in DSS-treated cells. All experiments have been repeated at least three times. Two-way ANOVA, a*P* < 0.05; b*P* < 0.001; c*P* < 0.0005. Cx43: Connexin 43; DSS: Dextran sulfate sodium; TEER: Trans-epithelial electrical resistance.

图示

描述已自动生成

**Figure 4 Dextran sulfate sodium induces inflammation in mice and carbenoxolone restores the normal phenotype.** A: A flowchart schematizing the *in vivo* experimental design. BALB/c male mice were distributed into four experimental groups, each comprised of five mice: (1) Control group that received normal drinking water with no carbenoxolone (CBX) injections; (2) CBX group that received normal drinking water with CBX injections starting day 11; (3) Dextran sulfate sodium (DSS) group where mice were administered with 2.5% DSS in their drinking water for 10 d but not subjected to any CBX injections; and (4) DSS + CBX group that received DSS-containing drinking water as well as CBX injections. Mice were given 30 mg/kg CBX *via* intraperitoneal injections from day 11 every other day to the end of the experiment; B: Variation of animal body weight over 21 d. DSS-exposed mice lost weight. Significance in body weight change was detected between days 4 and 12 in DSS-treated mice, and days 11 and 21 in CBX-injected mice only; C: Hematoxylin and eosin images showing the architecture of mice colon tissues from all experimental groups. Arrows indicate representative sites in each experimental condition. Scale bar 50 μm; D: Colon length was measured at the end of the experiment. DSS-treated mice showed significantly longer colons compared to the control group; E: Bar graphs showing the normalized gene expression of interleukin-1β and tumor necrosis factor-α in mouse colon tissues, as detected by quantitative polymerase chain reaction. Experiments were repeated five times and results are displayed as means ± SEM. One-way ANOVA, a*P* < 0.05. IL: Interleukin; CBX: Carbenoxolone; DSS: Dextran sulfate sodium; TNF-α: Tumor necrosis factor-α.

电脑萤幕画面

中度可信度描述已自动生成

**Figure 5 Dextran sulfate sodium increases connexin 43 and ten-eleven translocation-2 expressions *in vivo*.** A: Left panel: Histograms show the normalized gene expression of connexin 43 (Cx43) in mice colon tissues, as detected by quantitative polymerase chain reaction (qPCR). Middle panel: Western blot of Cx43 protein in mouse colon tissues. Right panel: Densitometric analysis of protein expression after normalization to β-actin. Dextran sulfate sodium (DSS)-treated mice had the highest expression of Cx43 in their colons; B: Left panel: Histograms display the normalized gene expression of ten-eleven translocation-2 (TET-2) in mouse colon tissues, as detected by qPCR. Middle panel: Western blot of TET-2 protein expression in mouse colon tissues. Right panel: Densitometric analysis of protein expression after normalization to β-actin. DSS exposure resulted in enhanced TET-2 transcription and carbenoxolone inhibition of gap junctions significantly increased TET-2 expression; C: Immunofluorescence images of colon tissues stained for Cx43 with the mean fluorescence intensity (MFI) analysis. Scale bar 20 μm; D: Immunofluorescence images of mouse colon tissues stained for CD68 and TET-2. Histograms reflect the MFI analysis. High levels of CD68+ cells correlated with greater expression of Cx43 and TET-2 in DSS-exposed mice. Scale bar 10 μm. Experiments were repeated five times. One-way ANOVA, a*P* < 0.05; b*P* < 0.005; d*P* < 0.0001. MFI: Mean fluorescence intensity; CBX: Carbenoxolone; DSS: Dextran sulfate sodium.

图示

中度可信度描述已自动生成

**Figure 6 Modulation of connexin 43 and ten-eleven translocation-2 expression in human colon tissues under pathological conditions.** A: Hematoxylin and eosin images of human colon tissues. Compared to normal (histopathologically unchanged) samples, tissues from inflamed (ulcerative colitis) and sporadic malignant colons show disorganization of colon crypts and infiltration of immune cells within the lamina propria. Scale bar 50 μm; B: Immunofluorescence images of CD68+ cells (macrophages) and connexin 43 (Cx43) show that Cx43 expression increases in inflamed tissues. Scale bar 10 μm; C: Immunofluorescence images of ten-eleven translocation-2 (TET-2) in human colon tissues (upper panel: Low magnification; lower panel: Higher magnification). TET-2 protein was minimally detected in ulcerative colitis and colon adenocarcinoma tissues. Scale bar 10 μm; D: Mean fluorescence intensity (MFI) analyses reflecting the expression of CD68, Cx43, and TET-2. One-way ANOVA, b*P* < 0.005; d*P* < 0.0001. MFI: Mean fluorescence intensity; TET: Ten-eleven translocation.

**Table 1 Quantitative polymerase chain reaction human and mouse primer sequences**

|  |  |  |
| --- | --- | --- |
| **Gene** | **Primer sequences, 5’ to 3’** | **Annealing temperature, °C** |
| *hCx43* | F: CTTCACTACTTTTAAGCAAAAGAG | 52 |
| R: TCCCTCCAGCAGTTGAG |
| *hTET-1* | F: TTCGTCACTGCCAACCTTAG | 60 |
| R: ATGCCTCTTTCACTGGGTG |
| *hTET-2* | F: CACTGCATGTTTGGACTTCTG | 60 |
| R: TGCTCATCCTCAGGTTTTCC |
| *hTET-3* | F: GCCCACAAGGACCAGCATAA | 60 |
| R: CGCAGCGATTGTCTTCCTTG |
| *hGAPDH* | F: TGGTGCTCAGTGTAGCCCAG | 52-62 |
| R: GGACCTGACCTGCCGTCTAG |
| *mCx43* | F: ACAGCGGTTGAGTCAGCTTG | 60 |
| R: GAGAGATGGGGAAGGACTTGT |
| *mTET-2* | F: CAAGGTGTGCTTGGCAATTTT | 60 |
| R: CATCACTGTGCGTCAATCAAGA |
| *mIl-1β* | F: CTCCACCTCAATGGACAGAA | 57 |
| R: GCCGTCTTTCATTACACAGG |
| *mTNF-* | F: AATGGCCTCCCTCTCATCAGT | 57 |
| R: CCACTTGGTGGTTTGCTACGA |
| *mGAPDH* | F: CATGGCCTTCCGTGTTCCTA | 58 |
| R: CCTGCTTCACCACCTTCTTGAT |

Cx43: Connexin 43; F: Forward; GAPDH: Glyceraldehyde 3-phosphate dehydrogenase; h: Human; Il-1β: Interleukin-1β; m: Mouse; R: Reverse; TET: Ten-eleven translocation; TNF-α: Tumor necrosis factor-α.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +19253991568

**Email:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**